Fending Off Private Label Competition: Innovation Is Key
This article was originally published in The Tan Sheet
Executive Summary
Innovative drug delivery, claims and packaging are keys to defending name brands from private label competition as consumers grow increasingly price sensitive
You may also be interested in...
FDA clears Zyrtec line extension
McNeil Consumer Healthcare gains regulatory approval for Zyrtec Allergy orally disintegrating tablets (cetirizine 10 mg). In a Sept. 3 1letter, FDA's Division of Nonprescription Clinical Evaluation green-lights McNeil's new drug application, submitted in November 2009, for 6-, 12-, 24- and 66-count cartons of the OTC. The Johnson & Johnson subsidiary has fulfilled the pediatric study requirements for the Zyrtec extension, FDA adds. J&J/McNeil declined to comment on when the tablets will launch. With generics readily available, Zyrtec and other brands seek innovative delivery formats to stay a step ahead of private label (2"The Tan Sheet" Oct. 6, 2008)
FDA clears Zyrtec line extension
McNeil Consumer Healthcare gains regulatory approval for Zyrtec Allergy orally disintegrating tablets (cetirizine 10 mg). In a Sept. 3 1letter, FDA's Division of Nonprescription Clinical Evaluation green-lights McNeil's new drug application, submitted in November 2009, for 6-, 12-, 24- and 66-count cartons of the OTC. The Johnson & Johnson subsidiary has fulfilled the pediatric study requirements for the Zyrtec extension, FDA adds. J&J/McNeil declined to comment on when the tablets will launch. With generics readily available, Zyrtec and other brands seek innovative delivery formats to stay a step ahead of private label (2"The Tan Sheet" Oct. 6, 2008)
FDA clears Zyrtec line extension
McNeil Consumer Healthcare gains regulatory approval for Zyrtec Allergy orally disintegrating tablets (cetirizine 10 mg). In a Sept. 3 1letter, FDA's Division of Nonprescription Clinical Evaluation green-lights McNeil's new drug application, submitted in November 2009, for 6-, 12-, 24- and 66-count cartons of the OTC. The Johnson & Johnson subsidiary has fulfilled the pediatric study requirements for the Zyrtec extension, FDA adds. J&J/McNeil declined to comment on when the tablets will launch. With generics readily available, Zyrtec and other brands seek innovative delivery formats to stay a step ahead of private label (2"The Tan Sheet" Oct. 6, 2008)